Get Flat 20% Discount on All Medications
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Natco Pharma challenges patent on Tamiflu


      Natco Pharma has challenged a patent on Tamiflu (Oseltamivir Phosphate)—a drug used in the treatment of bird and swine-flu infections, reports the PTI.

      Tamiflu, a USD 500 million market in the US and over USD 1 billion in global sales is invented by Gilead. Natco, in its filing to US FDA, alleged that Gilead's patent on the drug is invalid and sent a notice to Gilead to that extent. And, now the California-based Bio-pharmaceutical research firm has 45 days to challenge the patent seeking a 30-month ban on the new drug.

      Natco’s finance director and CFO Bhaskar Narayana, in an interview with CNBC-TV18 confirmed that they have filed an abbreviated new drug application (ANDA) that has been accepted by the US FDA. “This essentially means that after the expiry of the patent, the company would be entitled for 180 days exclusive marketing opportunity after the expiry of the patent in 2016,” he said.

      Feb 17, 2011


      Share this Article!

    Back to top^